Recs

3

Is AstraZeneca a Dividend Stock to Watch?

By | More Articles
October 26, 2012 | Comments (0)

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Shares of pharma giant AstraZeneca (NYSE: AZN  ) rose slightly today -- despite reporting mediocre third quarter earnings. Year-over-year revenue dropped, and sales took a hit after some of the company's high profile drugs lost patent protection this year.

In the following video, health care analysts Max Macaluso and David Williamson discuss these results, AstraZeneca's new CEO, and one of AstraZeneca's potential acquisition targets -- Amarin  (Nasdaq: AMRN  ) .

 

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air,  the success of its new triglyceride lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with our new premium research report. Click here now to keep reading.

 

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Max Macaluso has no positions in the stocks mentioned above. David Williamson owns shares of Amarin and Pfizer, but he holds no other position in any company mentioned. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2077982, ~/Articles/ArticleHandler.aspx, 5/21/2013 6:16:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 15,387.58 52.30 0.34%
S&P 500 1,669.16 2.87 0.17%
NASD 3,502.12 5.69 0.16%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/21/2013 4:00 PM
BMY $44.06 Up +0.30 +0.69%
Bristol-Myers Squi… CAPS Rating: ****
PFE $28.78 Up +0.08 +0.28%
Pfizer CAPS Rating: ****
AMRN $6.98 Down -0.07 -0.99%
Amarin Corp plc (A… CAPS Rating: ***
AZN $51.71 Up +0.21 +0.41%
AstraZeneca plc (A… CAPS Rating: ****

Advertisement